Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Dellinger

Internal Medicine Pasadena, CA Medical Doctor

NPI 1740691377 CMS profile 1387945

100 W California Blvd, Pasadena, CA 91105

Open in the dashboard

General payments

$65,267

80 records reported · program years 2019–2025

Research payments

$25,660

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Dellinger of Pasadena, CA is reported in the CMS Open Payments database as having received $65,267 across 80 general payments and $25,660 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,592 15
2024 General $17,057 20
2024 Research $1,842 1
2023 General $2,614 4
2023 Research $11,560 5
2022 General $8,251 10
2022 Research $11,204 6
2021 General $15,629 20
2021 Research $1,054 1
2020 General $5,625 10
2019 General $1,500 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Dellinger
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Joseph Dellinger were reported at $14,592. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Joseph Dellinger Internal Medicine median Middle half National median
2019 $1,500 $159 $48–$570 $163
2020 $5,625 $119 $33–$402 $114
2021 $15,629 $135 $37–$521 $132
2022 $8,251 $141 $42–$496 $149
2023 $2,614 $149 $45–$519 $160
2024 $17,057 $154 $47–$537 $164
2025 $14,592 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca UK Limited $49,448 59 payments
  2. Eisai Inc. $6,342 7 payments
  3. AstraZeneca AB $4,604 6 payments
  4. Bioverativ Therapeutics Inc. $1,625 4 payments
  5. AstraZeneca Pharmaceuticals LP $1,600 2 payments
  6. Sanofi US Services Inc. $1,500 1 payment
  7. AxoGen $149 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $65,118 79 payments
  2. Food and Beverage $149 1 payment
Products named General payments · program years 2019–2025
  1. BIVV020 $1,500 1 payment
  2. Avance Nerve Graft $149 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $18,619 7 payments
  2. UCB Biosciences Inc. $3,556 2 payments
  3. Regeneron Pharmaceuticals, Inc. $1,360 2 payments
  4. Ucb SA $1,063 1 payment
  5. Eli Lilly and Company $1,062 1 payment

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$54,164

Medicare's payments for the services billed

Medicare patients

185

Average age 74

Services billed

732

91 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 58%
Arthritis 56%
Chronic kidney disease 54%
Ischemic heart disease 48%
Heart failure 43%
Depression 33%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record